-
GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets
•
Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab Emirates, has announced a strategic collaboration with Guangdong Hecin Scientific Inc., a company based in China. As per the agreement, GSC is appointed as the exclusive agent for Hecin in the Middle East, covering key…
-
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China, has released its unaudited financial report for the first half of 2024. The company’s revenues for the period were on par with the same period in 2023, hitting RMB 8.57 billion (USD 1.2 billion), which…
-
Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China
•
Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has announced that it has obtained marketing approval from China’s National Medical Products Administration (NMPA) for its drug fulzerasib. This approval grants the company the green light to market fulzerasib, under…
-
China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages
•
The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply and Stabilizing Prices of Shortage Drugs,” outlining measures to enhance the oversight, analysis, and forecasting of drug supply and demand dynamics. The National Healthcare Security Administration (NHSA) is tasked with ongoing surveillance of drug prices…
-
China Commits to Optimizing Market Access for Emerging Sectors and Global Scientific Collaboration
•
The General Office of the Communist Party of China (CPC) Central Committee and the State Council have issued the “Opinions on Improving the Market Access System,” consolidating market access management measures under a unified national negative list. This list encompasses existing regulations from laws, administrative statutes, State Council decisions, and…
-
Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China
•
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster drug Lucentis (ranibizumab) has received market approval from the National Medical Products Administration (NMPA). This regulatory nod positions the product as the first biosimilar of its kind to be approved in China. Ranibizumab, a vascular…
-
BrightGene Bio Receives FDA Clearance for Generic Eribulin APIs, Advancing in Breast Cancer Treatment
•
BrightGene Bio-Medical Technology Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange (SHA: 688166), has announced the receipt of a First Adequate Letter from the US FDA for the active pharmaceutical ingredients (APIs) of its generic version of Eisai’s Halaven (eribulin), signifying that the drug has successfully…
-
Sisram Medical Reports 2024 Interim Revenues with Growth in Key Regions and New Product Launches
•
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released its unaudited interim financial report for 2024, showing revenues of USD 168.7 million, a slight decrease of 1.7% year-on-year (YOY). The company’s regional revenue breakdown indicates growth in the Asia Pacific, Europe, Middle East, and…
